Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra-concentrated rapid acting insulin aspart - Arecor

Drug Profile

Ultra-concentrated rapid acting insulin aspart - Arecor

Alternative Names: AT-278; Ultra-concentrated rapid acting insulin - Arecor

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arecor
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Diabetes mellitus
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 20 May 2024 Efficacy, safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Type 2 diabetes mellitus released by Arecor Limited
  • 12 Feb 2024 Arecor Limited completes a phase-I trial in Type 2 diabetes mellitus (In adults, In elderly) in Austria (SC, Injection) (NCT05754424)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(Treatment-experienced) in Austria (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top